栾鑫 研究员、博士生导师、中药系统药理学研究中心主任

招生专业 院系名称 专业大类 一级学科 专业代码/专业名称 学位类型 招生类型 交叉科学研究院 医学 中药学 100800/中药学 学术学位 博士/硕士 交叉科学研究院 医学 中药学 105600/中药学 专业学位 硕士

教育及任职经历 2007.9-2011.7 中国药科大学药学院 学士 2011.9-2016.6 上海交通大学医学院 博士 2015.9-2016.4 美国密西根大学药学院 联合培养博士研究生 2016.7-2018.7 美国密西根大学药学院 博士后研究员 2018.8-2020.9 上海中医药大学交叉科学研究院 副研究员、硕士生导师 2020.10-至今 上海中医药大学交叉科学研究院 研究员、博士生导师、中心主任

个人简介与研究方向 栾鑫，博士，上海中医药大学交叉科学研究院研究员，博士生导师。研究工作聚焦中药来源抗肿瘤功能分子发现及靶向药物递送研究。近年来在Adv. Sci., Trends Cancer, Trends Mol. Med., Nat. Prod. Rep., JCI Insight, APSB, Biomaterials, Small, J. Med. Chem.等期刊以第一/通讯作者发表SCI论文40余篇，引用2200余次，其中IF>10分论文15篇，ESI高被引论文2篇，平均IF>9，单篇最高引用560余次，申请专利8项，先后入选上海市东方学者、上海市青年科技启明星、上海市青年东方学者、上海市晨光计划、中华中医药学会青年托举人才（A类），主持国家、上海市及上中医项目10项。兼任上海市药学会药理专委会委员、青委会主任，中华中医药学会青年委员等。J Ethopharmacol，Chinese Medicine and Culture，中国药理学通报等多本期刊编辑及多本SCI杂志审稿人，参与编写人卫版十四五规划教材3部。

近五年以第一负责人承担的科研课题与经费 序号课题类型项目时间项目经费（万元）备注 1 国家自然科学基金面上项目 2022.01-2025.12 55 主持 2 国家自然科学基金青年项目 2020.01-2022.12 21 主持 3 上海市东方学者 2022.01-2024.12 100 主持 4 上海市青年科技启明星计划2022.05-2025.04 40 主持 5 中华中医药学会青年人才托举（A类） 2021.12-2024.06 6 主持 6 上海市科技行动创新计划2021.06-2024.05 20 主持 7 上海市青年科技英才扬帆计划 2018.10-2021.10 20 主持 8 上海市青年东方学者特聘教授 2019.01-2021.12 60 主持 9 上海市晨光计划 2019.01-2020.12 6 主持 10 上海中医药大学高水平大学人才引进 2021.05-2024.04 100 主持

中药来源抗肿瘤分子发现及纳米靶向药物

1. Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, Nagle DG, Chen HZ*, Zhang WD*, Luan X*. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer. Small, 2023, e2207778. (IF 15.1)

2. Jin J#, Wu Y#, Zhao Z#, Wu Y, Zhou YD, Liu S, Sun Q, Yang G, Lin J, Nagle DG, Qin J, Zhang Z, Chen HZ, Zhang W*, Sun S*, Luan X*. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight, 2022, 7(22): e160606. (IF 9.4)

3. Lu L#, Zhang H#, Zhou Y#, Lin J, Gao W, Yang T, Jin J, Zhang L, Nagle DG, Zhang W, Wu Y*, Chen H*, Luan X*. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Theranostics, 2022, 12(7):3456-3473. (IF 11.6)

4. Bian HT#, Shen YW#, Zhou YD, Nagle DG, Guan YY*, Zhang WD*, Luan X*. CD47: Beyond an immune checkpoint in cancer treatment. Biochim Biophys Acta Rev Cancer, 2022, 1877(5):188771. (IF:11.4)

5. Zheng X#, Zhang L#, Ju M, Liu L, Ma C, Huang Y, Wang B, Ding W, Luan X*, Shen B*. Rational Modulation of BODIPY Photosensitizers to Design Metal-Organic Framework-Based NIR Nanocomposites for High-Efficiency Photodynamic Therapy in a Hypoxic Environment. ACS Appl Mater Interfaces, 2022, 14(41):46262-46272. (IF 10.3)

6. Lu S, Lin J, Jin J, Zhang L, Guan Y, Chen H, Wu Y*, Zhang W*, Luan X*. Tachyplesin I and its derivatives: A pharmaco-chemical perspective on their antimicrobial and antitumor potential. Expert Opin Drug Discov, 2022, 17(12):1407-1423. (IF 7.0)

7. Lv C#, Huang Y#, Huang R, Wang Q, Zhang H, Jin J, Lu D, Zhou Y, Shen Y, Zhang W*, Luan X*, Liu S*. Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol Ther Oncolytics, 2022, 24:340-354. (IF 6.3)

8. Zhu C#, Guan X#, Zhang X, Luan X, Song Z, Cheng X, Zhang W*, Qin JJ*. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer, 2022, 21(1):159. (IF 41.4)

9. Luan X#, Wu Y#, Shen YW, Zhang H, Zhou YD, Chen HZ, Nagle DG*, Zhang WD*. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep, 2021, 38(1):7-17. (IF 15.1，封面论文)

10. Huang R#, Zhang L#, Jin J#, Zhou Y, Zhang H, Lv C, Lu D, Wu Y, Zhang H, Liu S, Chen H*, Luan X*, Zhang W*. Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction. Acta Pharm Sin B, 2021, 11(11):3481-3492. (IF 14.9)

11. Lin J#, Jin J#, Shen Y#, Zhang L, Gong G, Bian H, Chen H, Nagle DG, Wu Y*, Zhang W*, Luan X*. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics, 2021, 11(17):8337-8349. (IF 11.6)

12. Luan X#, Yuan H#, Song Y#, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S*, Gao W*, Sun D*. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 2021, 275:120910. (IF 15.3)

13. Wu Y#, Lu D#, Jiang Y, Jin J, Liu S, Chen L, Zhang H, Zhou Y, Chen H, Nagle DG, Luan X*, Zhang W*. Stapled Wasp Venom-Derived Oncolytic Peptides with Side Chains Induce Rapid Membrane Lysis and Prolonged Immune Responses in Melanoma. J Med Chem, 2021, 64(9):5802-5815. (IF 8.0，封面论文)

14. Zhang LJ#, Huang R#, Shen YW#, Liu J, Wu Y, Jin JM, Zhang H, Sun Y*, Chen HZ*, Luan X*. Enhanced anti-tumor efficacy by inhibiting HIF-1α to reprogram TAMs via core-satellite upconverting nanoparticles with curcumin mediated photodynamic therapy. Biomater Sci, 2021, 9(19):6403-6415. (IF 7.5，封面论文)

15. Gong G#, Shen YL#, Lan HY#, Jin JM, An P, Zhang LJ, Chen LL, Peng W*, Luan X*, Zhang H*. The Cyr61 Is a Potential Target for Rotundifuran, a Natural Labdane-Type Diterpene from Vitex trifolia L., to Trigger Apoptosis of Cervical Cancer Cells. Oxid Med Cell Longev, 2021, 2021:6677687. (IF 7.3)

16. Shen YW, Zhou YD, Chen HZ, Luan X*, Zhang WD*. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity. Trends Cancer, 2021, 7(6):511-524. (IF 19.1)

17. Huang R#, Shen YW#, Guan YY, Jiang YX, Wu Y, Rahman K, Zhang LJ*, Liu HJ*, Luan X*. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology. Acta Biomater, 2020, 116:1-15. (IF 10.6)

18. Shen YW, Zhou YD, Luan X*, Zhang WD*. Blocking CTGF-Mediated Tumor-Stroma Interplay in Pancreatic Cancer. Trends Mol Med, 2020, 26(12):1064-1067. (IF 15.2)

19. Jin J#, Wu Y#, Chen J#, Shen Y, Zhang L, Zhang H, Chen L, Yuan H, Chen H*, Zhang W*, Luan X*. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics, 2020, 10(22):10141-10153. (IF 11.6，封面论文)

20. Luan X#, Guan YY#, Liu HJ, Lu Q, Zhao M, Sun D, Lovell JF, Sun P, Chen HZ*, Fang C*. A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia. Adv Sci, 2018, 5(8):1800034. (IF 17.5，封面论文)

21. Luan X#, Sansanaphongpricha K#, Myers I, Chen H, Yuan H*, Sun D*. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin, 2017, 38(6):754-763. (IF 7.1，ESI高被引)

22. Luan X#, Guan YY#, Lovell JF, Zhao M, Lu Q, Liu YR, Liu HJ, Gao YG, Dong X, Yang SC, Zheng L, Sun P, Fang C*, Chen HZ*. Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel. Biomaterials, 2016, 95:60-73. (IF 15.3)

23. Guan YY#, Luan X#, Xu JR, Liu YR, Lu Q, Wang C, Liu HJ, Gao YG, Chen HZ*, Fang C*. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials, 2014, 35(9):3060-70. (IF 15.3)